Here is the reformatted article.

The FDA Weighs Easing Restrictions on Peptide Injections Amid Growing Popularity and Safety Concerns

The U.S. Food and Drug Administration (FDA) is scheduled to hold a pivotal meeting in July 2025 to review whether to ease restrictions on seven peptide injections. Simultaneously, regulators in Australia are intensifying enforcement against unapproved peptide products. These substances, which lack comprehensive human safety data and full FDA approval, have surged in popularity through social media and wellness influencers.

FDA Regulatory Review

Meeting Details

The FDA will convene its Pharmacy Compounding Advisory Committee on July 23-24, 2025, to review seven specific peptide injections. The committee will consider whether these substances should be moved from a restrictive category reserved for drugs deemed too risky for routine compounding to a list of substances that can be routinely compounded by licensed pharmacies.

The seven peptides under review include BPC-157 and TB-500. Five other peptides are also under consideration but have not been publicly identified. The FDA notice cites possible medical uses for review, such as using BPC-157 to treat ulcerative colitis.

Regulatory History

Under the previous administration, the FDA added more than a dozen popular peptides to a list of substances that should not be produced by compounding pharmacies. At that time, FDA advisers voted that the peptides did not meet safety criteria for compounding, citing "significant safety risks" due to limited human testing.

When restricting injectable peptides in 2023, the FDA cited potential safety risks including cancer and liver, kidney, and heart problems. Pharmacies violating these restrictions risk fines, legal action, or loss of state licenses.

FDA Position

FDA scientists have posted documents expressing concerns about insufficient evidence for several peptide therapies. The scientists stated there is not enough data to support changing the designation for any of the seven peptides under review, citing inadequate human clinical trials and concerns about quality, stability, and consistency.

"There is not enough data to support changing the designation for any of the seven peptides under review."

Many of the FDA advisers and staff involved in the previous decisions to restrict peptides no longer work at the agency.

Statements from Public Officials

Health Secretary Robert F. Kennedy Jr. has repeatedly stated his support for loosening peptide regulations. He has claimed that the previous administration "illegally moved" peptides to the restricted list and has stated he has used peptides himself for injuries. Kennedy has expressed concern about "gray market" products being "very, very substandard."

Several members of Congress, including Senator Tommy Tuberville, have asked Kennedy to lift peptide production limits.

Advisory Committee Composition

Seven of the 14 members of the FDA's advisory committee have ties to businesses or clinics involved in peptide therapies, including doctors who sell peptide injections and a state senator whose family owns a compounding pharmacy. The Department of Health and Human Services stated that all members met federal ethics requirements. The committee's recommendations are non-binding.

Industry and Market Context

The compounding pharmacy industry has argued that FDA restrictions have created an illicit market of imported chemicals not subject to U.S. drug standards.

Wellness clinics offer peptide injections with monthly membership fees reaching thousands of dollars. Dietary supplement makers have begun incorporating peptides into capsules, powders, and gummies. Online platforms host overseas suppliers selling various peptides labeled "for research use only," which lawyers have stated is an attempt to circumvent FDA regulations. Overseas suppliers offer peptide varieties for as low as $5 per vial.

U.S. peptide-related searches reached 10.1 million in January 2026, with approximately 60% related to GLP-1 medications. Searches for "longevity peptides" have significantly increased year-over-year.

Peptide Background

Peptides are short chains of amino acids that function as the building blocks of proteins. They can influence how the body functions at a cellular level, acting as chemical messengers involved in processes such as growth, metabolism, and healing. The human body naturally produces some peptides.

Some peptides have FDA approval for specific medical uses, including insulin and GLP-1 medications (such as semaglutide) for diabetes and weight management. Over 80 peptides are approved for use by the FDA.

The peptides under review, including BPC-157 and TB-500, are marketed for injury healing, muscle building, and anti-aging effects. Most have not undergone FDA safety reviews, and there is limited scientific research supporting these claims. Several peptides, including BPC-157 and TB-500, are banned by international sports authorities as doping substances.

Scientific Evidence and Concerns

Limited Human Research

For many peptides promoted online for injury healing, anti-aging, and performance enhancement, high-quality human evidence is limited. Claims for peptides such as BPC-157, TB-500, and GHK-Cu are primarily based on laboratory studies in cells or animals.

• BPC-157: Some animal studies suggest potential for new blood cell growth, inflammation reduction, and tissue healing in rats. Human evidence is extremely limited, consisting of three small studies that lacked control groups. No large-scale clinical trials exist.
• GHK-Cu: Limited evidence suggests a role in collagen production and wound healing in mice, but these findings have not been confirmed in humans.

Dr. Paul Knoepfler, a cell and molecular biologist at the University of California, Davis, has stated that most research on these experimental peptides has been conducted in animals or labs, not humans. He has cautioned that while the science behind some applications can be theoretically sound, using untested peptides carries risks of serious harm. He noted that animal studies suggest BPC-157 may aid tissue repair by accelerating blood vessel growth, but this could theoretically encourage the growth of pre-cancerous cells.

Dr. Alexander Weber, an orthopedic surgeon at the University of Southern California, has published a review stating there is not enough data to support the use of these peptides.

Potential Risks

The following risks have been identified by experts and regulators:

• Product Quality: Unregulated peptides may be mislabeled, contaminated, or incorrectly dosed. U.S. plastic surgeon Dr. Terry Dubrow has noted that up to 70% of tested peptides do not contain the claimed ingredients and may contain heavy metals or toxins.
• Biological Risks: Peptides influencing growth, repair, or hormonal pathways could potentially stimulate unintended processes, including promoting the growth of existing tumors or disrupting normal endocrine function.
• Injection Risks: Self-administration without sterile technique carries risks including infections, abscesses, and tissue damage. Unsafe injecting practices can also transmit blood-borne viruses such as HIV and hepatitis C.

"While animal data suggests powerful effects on cell function, there are no gold-standard randomized human trials demonstrating efficacy."
— Dr. Jon LaPook, CBS News Chief Medical Correspondent

Australian Regulatory Actions

Enforcement

The Therapeutic Goods Administration (TGA) has intensified enforcement against unapproved peptide products, adding unapproved peptides to its priority focus areas. The TGA has stated the decision is a "deliberate, risk-based response" to an evolving market.

Enforcement measures may include product seizures, infringement notices, and civil or criminal penalties. Recent joint operations by the TGA, Australian Border Force, and Victorian Police seized peptides and other drugs valued at over $2 million.

Regulatory Status

In Australia, regulated injectable peptides are classified as prescription-only medicines. The TGA lists unapproved synthetic peptides such as BPC-157 as Schedule 4 poisons. Many products are sold online as "research chemicals" labeled "not for human consumption," despite packaging and marketing that suggests intended human use.

The TGA has issued safety advisories warning against importing unapproved peptide products. Professor Anthony Lawler, TGA deputy secretary, has noted risks including unknown ingredients, lack of sterility, and financial loss if products are intercepted at the border.

Health Incidents in Australia

Emergency departments in Victoria, Australia, have reported an increase in patients with severe side effects from illegal peptide use, including vomiting, abdominal cramping, and chest pain resembling heart attacks. Doctors have reported cases of serious skin infections from contaminated peptides, requiring skin grafts or amputations.

A death linked to growth-stimulating peptides (CJC 1295 and ipamorelin) prescribed by a medical practitioner is under investigation by the Coroner's Court.

Patients have been taking up to 10 times the recommended dose, sometimes daily instead of weekly.

Expert Commentary

Dr. Mark Putland, director of emergency medicine at Royal Melbourne Hospital, has reported that some patients initially suspected of heart attacks were actually suffering from peptide complications, with symptoms persisting for days.

Dr. Tim Piatkowski from the University of Queensland, who operates the Steroid QNECT hotline, has reported receiving about 30 calls per week from peptide users, including a 16-year-old seeking advice. He has stated that many young people view peptides as safer than anabolic steroids, but there is limited clinical evidence on safety.

Dr. Michael Bonning of the Australian Medical Association has stated that claims of benefits are significantly exaggerated and lack scientific evidence from clinical trials. He has advised against purchasing unapproved peptide products from the internet due to the absence of regulation and unknown contents.

Recommendations from Researchers

A comment piece published in The Lancet Child & Adolescent Health in May 2026, authored by Dr. Timothy Piatkowski, Assistant Professor Kyle T. Ganson, and Associate Professor Jason Nagata, has called for coordinated regulatory action. The authors recommend disrupting digital supply pathways, addressing drivers of demand, training clinicians to identify and respond to peptide use, targeting influencer marketing and affiliate-linked sales, and implementing stronger import controls.

Social Media and Marketing

TikTok content tagged "peptides" had over 230 million views as of April 2026, according to research. U.S. peptide-related searches reached 10.1 million in January 2026, with millions of searches for performance-related, anti-aging, and healing peptides.

"The broad marketing of these products is a red flag, given their usual lack of rigorous testing and FDA approval."
— Dr. Monica Wang, Harvard T.H. Chan School of Public Health

Dr. Monica Wang, an associate professor at the Harvard T.H. Chan School of Public Health, has identified the broad marketing of these products as a "red flag," noting their usual lack of rigorous testing and FDA approval. She has suggested that the desire for simple solutions to complex health problems, combined with e-commerce and social media algorithms, contributes to interest in these unproven treatments.